PharmAbcine Enters Collaboration with MSD Focused on Clinical Evaluation of TTAC-0001 in Combination with KEYTRUDA® (pembrolizumab) in Recurrent Glioblastoma and Breast Cancer
PharmAbcine Inc., a clinical-stage biotech company developing novel antibody therapeutics for multiple cancer indications, announces it has entered into a collaborative agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA), through a subsidiary, to evaluate PharmAbcine’s anti-VEGFR2 mAb, TTAC-0001, in combination with MSD’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with recurrent glioblastoma multiforme (rGBM) and metastatic triple-negative breast cancer (TNBC).
PharmAbcine’s lead candidate TTAC-0001, an investigational therapy, is a highly selective and potent anti-VEGFR2 (KDR/flk-1) mAb in clinical development for rGBM indications. VEGFR2 is over-expressed in most malignant tumors, such as gastric, liver, non-small cell lung cancer (NSCLC), ovarian, brain, colorectal, and breast cancers and this signaling pathway is a key regulator for tumor angiogenesis. Increased understanding of the role of VEGF/VEGFR2 in the tumor microenvironment (TME) supports the rationale for evaluating TTAC-0001 in combination with KEYTRUDA.
“The combination of the anti-VEGFR2, TTAC-0001 and the anti-PD-1 therapy, KEYTRUDA in this study has the potential to build upon the responses already observed with each of these molecules as monotherapies,” said Jin-San Yoo, Ph.D., President and CEO of PharmAbcine. “There is a strong biologic rationale to combine these therapies as their complementary mechanisms of action may enhance the anti-tumor activity.”
Under the terms of the collaboration, PharmAbcine will conduct international Phase I/II studies to evaluate the potential clinical synergy of combining TTAC-0001 with KEYTRUDA.
About PharmAbcine Inc.
PharmAbcine is a leading clinical stage biologics company that develops fully human therapeutic antibody (mAb) and next generation multispecific antibody therapeutics based on in-house developed novel platform, DIG-Body, PIG-Body and TIG-Body using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.
PharmAbcine’s fully human antibody libraries and innovative selection system are our proprietary assets. PharmAbcine provides antibody generation services by using antibody library and selection systems. PharmAbcine also provides co-development opportunities with novel antibodies.
Under the collaboration with SAMSUNG MEDICAL CENTER, PharmAbcine has >300 patients derived cancer stem cell libraries and its animal model system for evaluating internal pipeline development.
TTAC-0001(=Tanibirumab), anti-KDR neutralizing fully human IgG with unique cross species cross reactivity has completed its Phase IIa recurrent GBM trial in Australia in August 2017 and its final report will be available early in 2018. Promising molecule to combine with immune checkpoint blockade is open for out-licensing, co-development and combination clinical trials.
PMC-001(=DIG-KT), next generation bispecific antibody neutralizing both VEGF-KDR and Angiopoietin-TIE2 pathways is superior to bevacizumab and Tanibirumab in preliminary studies. It also overcomes the Avastin resistant brain tumor growth. PMC-002, PMC-003, PMC-004 are derivative molecules from PMC-001.
PMC-201, next generation bispecific antibody neutralizing both VEGF-KDR and Notch-DLL4 pathways overcomes anti-cancer drug resistant tumor growth.
PMC-005B, Anti-EGFRviii truly specific fully human IgG with internalization property is perfect for ADC, CAR-T and CAR-NK purpose and is open for codevelopment or out-licensing.
PMC-309a-z, anti-VISTA fully human antibodies collection as either agonistic or antagonistic.
"3G-System" platform provides high performing production cell lines and we do have
PMC-901, bevacizumab biosimilar cell line with 3g/L productivity.
PMC-902, aflibercept biosimilar cell line with >3g/L productivity.
Additional information about PharmAbcine is available through its
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults, with a median survival of less than 15 months from diagnosis and recurrences frequently within a year following the initial treatment. Chemotherapy, radiation and surgery are the primary initial treatments; chemotherapy and surgery may be possible for recurrent disease, with limitations in using radiation dependent on the site of recurrence. Avastin is approved as an active treatment option (single agent) for patients with rGBM who have failed previous TMZ and radiation therapy.
Breast cancer is the most common cancer in women – it is estimated that more than 250,000 new cases will be diagnosed in the US in 2017. 20% of breast cancers lack receptors for three common hormones (estrogen, progesterone and HER2) and are thus called triple-negative breast cancers (TNBC). Treatment options for TNBC are limited, and despite therapy recurrences are frequent and aggressive. Consequently, novel treatment strategies for TNBC are of high need.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.
Dr. Sung Woo Kim
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Savi Adds Supply Chain Star Johannes Giloth to Advisory Board21.2.2018 16:02 | Tiedote
Savi®, an innovator in big data/machine learning analytic solutions, supply chain management software, and sensor technology, today announced that Johannes Giloth has joined its board of advisers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005117/en/ Johannes Giloth (Photo: Business Wire) Giloth is a long-time leader in procurement, supply chain and manufacturing. He currently serves as Chief Procurement Officer and Senior Vice President of Operations at Nokia where he is in charge of every aspect of operations accountability worldwide — from demand planning to execution, procurement to manufacturing. “Johannes understands the impact the explosion of data will have on the supply chain. And his tremendous success as an innovative supply chain leader proves he knows what companies need to transform their supply chains,” said Rich Carlson, CEO of Savi Technology. “I’m thrilled to have him join Savi’s advisory board. As
Mavenir Unveils Its Industry First Mobile-Native UCaas Solution, Entering into a New UCC Market Category21.2.2018 16:00 | Tiedote
Mavenir, a leader in mobile network transformation, today announced its industry first Mobile-Native Unified Communications and Collaboration as a Service (mUCaaS) solution, uniquely designed to address the specific mobility needs of SOHO and SMBs. Using mobile native wireless technologies while still supporting current communications desktop usage is a complete paradigm shift compared to traditional UCaaS offerings. Leveraging Mavenir’s expertise in mobile networks with Voice over LTE (VoLTE) and Rich Communication Services (RCS), the solution provides new recurring-revenue opportunities for mobile network operators (MNOs) while addressing the real business need for truly mobile communications for the workforce. MNOs are under pressure in the consumer market with flat growth, an intensive price war on voice and data plans, and fierce competition from OTT applications. The Enterprise market offers a better outlook with UCaaS telephony and messaging projecting growth of 15.2% CAGR1 2016
Medical Technology Leaders to Discuss Open Data During World Patient Safety, Science & Technology Summit21.2.2018 16:00 | Tiedote
The medical technology field spans a multi-billion dollar market, and corporate competitiveness has long been viewed as the key to staying ahead. But Joe Kiani, Chairman, and CEO of the medical technology company, Masimo, is bringing fierce competitors together for the sake of patient safety. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005514/en/ Joe Kiani, Founder and Chairman of the Patient Safety Movement Foundation, discusses the importance of open data and interoperability of medical devices. (Photo: Business Wire) As a strong advocate for patient safety, Kiani founded the Patient Safety Movement Foundation to stem the needless deaths that occur in hospitals every day through preventable medical error. The goal is zero preventable deaths by 2020. One of the ways to reach such an aggressive goal, says Kiani, is a concept called “interoperability” and he wants to use open data to create a “Patient Data Super Highw
Mavenir and ADVA Ensemble Partner to Deliver Enterprise LTE Solutions to Managed Service Providers and Enterprises21.2.2018 15:00 | Tiedote
Mavenir, focused on transforming mobile network economics for Communications Service Providers, and Ensemble, a Division of ADVA Optical Networking, the leader in Edge NFV solutions, have partnered to provide a complete end-to-end solution for Enterprise LTE. The Enterprise LTE Solution empowers mobile network operators with a revenue-generating solution offering for businesses looking to replace outdated and expensive hardware-based wireless networks. Enterprise solutions require low cost white box architectures that are zero touch from an install perspective. To add complete LTE wireless connectivity to that solution allows the enterprise to install their own partial or complete LTE enterprise wireless that is capable of supporting CBRS and multicarrier solutions. The total global revenue for the private LTE addressable market in industrial and commercial IoT will reach $118.5 billion in 20231. Leveraging NFV as a platform for new and innovative applications, Ensemble and Mavenir hav
The Russian Export Center Will Be Presenting Innovative Russian Solutions at the Mobile World Congress in Barcelona for the First Time21.2.2018 14:21 | Tiedote
The Russian Export Center will be introducing home-grown, Russian technology at the 2018 Mobile World Congress (MWC) in Barcelona for the first time. Seventeen Russian companies will showcase their unique, powerful and competitive solutions to a world audience from February 26th to March 1st, from the Russian Booth (Pavilion No. 6, booth 6H20 and 6I11). Information about Russian companies attending is available via the link below: https://drive.google.com/file/d/1pNZ5d8ZOSrC5Ltf_ro_oQVZoo2ylnWqY/view A special business program is organized for the Russian booth, to create opportunities for Russian companies to enter the international market and non-Russian companies to promote their business in Russia. We would like to welcome media and attendees to special events at the Russian Export Center exposition including: - A special session with the leading Russian newspaper "Kommersant", titled "New business opportunities in the digital age" involving Russian and foreign experts (February 26
HSL to Launch a MaaS Interface Open to Everyone on 2 April21.2.2018 14:18 | Tiedote
HSL is currently building the world’s first completely open public transport ticketing interface. The interface will allow operators in Finland and abroad to incorporate HSL’s tickets into their array of services. The interface will open for commercial purposes at https://sales-api.hsl.fi on 2 April. HSL is also inviting operators outside the transport sector to develop innovative, new mobility services using the interface. Technical development of the interface will continue and in the future, other tickets may be made available via the interface, in addition to single tickets. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005630/en/ On 19 February, a so called sandbox environment was opened whereby developers can acquaint themselves with the characteristics of the interface’s production environment, and test the compatibility of their own interfaces with the HSL OpenMaas interface. Schedule for HSL’s OpenMaas service
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme